Zura Bio Limited - Class A Ordinary shares (ZURA)

Discover the stocks with unexpected trading volume in today's session on the US markets.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

ZURA stock results show that Zura Bio beat analyst estimates for earnings per share the second quarter of 2024.

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the second quarter of 2024.

Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements

There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment.

Penny stocks to buy carry a considerable amount of risk and extra sue dilligence is required before buying shares.

ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the fourth quarter of 2023.

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session.